Celastrol ameliorates hypoxic-ischemic brain injury in neonatal rats by reducing oxidative stress and inflammation.

ABSTRACT:

Background

Hypoxic-ischemic encephalopathy (HIE) is caused by perinatal hypoxia and subsequent reductions in cerebral blood flow and is one of the leading causes of severe disability or death in newborns. Despite its prevalence, we currently lack an effective drug therapy to combat HIE. Celastrol (Cel) is a pentacyclic triterpene extracted from Tripterygium Wilfordi that can protect against oxidative stress, inflammation, and cancer. However, whether Cel can alleviate neonatal hypoxic-ischemic (HI) brain damage remains unclear.

Methods

Here, we established both in vitro and in vivo models of HI brain damage using CoCl₂-treated PC12 cells and neonatal rats, respectively, and explored the neuroprotective effects of Cel in these models.

Results

Analyses reveal

SUBMITTER: Hu Y 

PROVIDER: S-EPMC11772252 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature